Search Results 671-680 of 17391 for alopecia
Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;; Women of child bearing potential (WCBP), defined ...
It requires heart and empathy to go with all the knowledge that you gained here at the Mayo Medical School. Whatever your specialty, as a physician, you do have ...
... alopecia. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia. Unwilling or unable to participate in all required study evaluations and ...
Recovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy (excluding alopecia) prior to initiation of study drug ...
... alopecia; Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of ...
The spongy tissue inside the bones, called bone marrow, making more red blood cells called reticulocytes to correct anemia. This might happen after blood loss.
Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...
Pediatric cancer experts use a team approach to diagnose and treat children who have brain tumors.
... alopecia and the criteria outlined; Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinomas ...
... alopecia, ototoxicity and neuropathy. Patients must not be receiving any other investigational anti-cancer agents while on study. Patients must not have ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift today can have 5X the impact on AI research and technology. But hurry — the match challenge ends 9/19.